

**CHANGE OF  
CORRESPONDENCE ADDRESS  
Patent**

Address to:

Mail Stop Post Issue  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Patent Number	6,200,560
Issue Date	3/13/2001
Application Number	09/470,618
Filing Date	12/22/1999
First Named Inventor	Couto, Linda B.
Attorney Docket Number	1011.CIPI

Please change the Correspondence Address for the above-identified patent to:

☒ The address associated with Customer Number

24536

OR

☐ Firm or  
Individual Name

**Address**

City

State

ZIP

Country

Telephone

Email

This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124)

This form will not affect any "fee address" provided for the above-identified patent. To change a "fee address" use the "Fee Address Indication Form" (PTO/SB/47).

I am the:

☐

Patentee.

☒

Assignee of record of the entire interest. See 37 CFR 3.71.  
Certificate under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☐

Attorney or agent of record. Registration Number \_\_\_\_\_

Signature

*Elizabeth Lassen*

Typed or  
Printed Name

Elizabeth Lassen, Managing IP Counsel, Genzyme Corporation

Date

1/28/08

Telephone (508) 270-2553

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 5 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Post Issue, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: Genzyme Corporation

Application No./Patent No.: 6,200,560 Filed/Issue Date: 3/13/2001

Entitled: Adeno-associated virus vectors for expression of factor VIII by target cells

Genzyme Corporation a Massachusetts corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or  
2. ☐ an assignee of less than the entire right, title and interest  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %)

In the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Inventors To: Avigen, Inc.  
The document was recorded in the United States Patent and Trademark Office at Reel 010390, Frame 0989, or for which a copy thereof is attached.
2. From: Avigen, Inc. To: Genzyme Corporation  
The document was recorded in the United States Patent and Trademark Office at Reel 020010, Frame 0567, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Elizabeth Lassen  
Signature

1/28/02  
Date

Elizabeth Lassen

(508) 270-2553

Printed or Typed Name

Telephone Number

Managing IP Counsel, Genzyme Corporation

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Genzyme Corporation  
500 Kendall Street  
Cambridge, MA 02142  
T 617-252-7500

**SIGNATURE AUTHORITY**

I, Thomas J. DesRosier, Senior Vice President and General Counsel of Genzyme Corporation hereby appoint Madge K. Shafmaster, Senior Vice President and Chief Patent Counsel; Bart G. Newland, Vice President, Intellectual Property; Richard Allison, Managing Intellectual Property Counsel; Elizabeth Lassen, Managing Intellectual Property Counsel; and Jennifer L. Dupré, Managing Intellectual Property Counsel, all of Genzyme Corporation, with full power and authority to transact any and all business before the United States Patent and Trademark Office, and any foreign counterpart patent office, with the powers of a Corporate Officer of Genzyme Corporation.

Date: January 24, 2008

A handwritten signature in black ink, appearing to read "Thomas J. DesRosier", written over a horizontal line.

Thomas J. DesRosier  
Senior Vice President and General Counsel  
GENZYME CORPORATION